Company · CIK 0000906709 · SIC 2834 — Pharmaceutical Preparations · Nasdaq
NEKTAR THERAPEUTICS · NKTR
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 AForm 4 → | Sep 25, 8:29 pm EDT | Roy A WhitfieldDirector | 2,000 | — | — | 16,417 | — | |
| Sep 23, 2026 AForm 4 → | Sep 25, 8:26 pm EDT | R Scott GreerDirector | 2,000 | — | — | 22,239 | — | |
| Sep 23, 2026 AForm 4 → | Sep 25, 8:22 pm EDT | Robert ChessDirector | 2,000 | — | — | 19,019 | — | |
| Sep 23, 2026 AForm 4 → | Sep 25, 8:20 pm EDT | Diana BrainardDirector | 2,000 | — | — | 3,904 | — | |
| Sep 23, 2026 AForm 4 → | Sep 25, 8:18 pm EDT | Jeffrey Robert AjerDirector | 2,000 | — | — | 4,277 | — | |
| Aug 18, 2026 SForm 4 → | Aug 20, 7:05 pm EDT | Jonathan ZalevskyChief R&D Officer | 186 | $71.98 | $13,388 | 9,570 | −1.91% | |
| Aug 18, 2026 SForm 4 → | Aug 20, 7:03 pm EDT | Howard W RobinPresident & CEO, Director | 418 | $71.98 | $30,088 | 54,627 | −0.76% | |
| Jun 30, 2026 SForm 4 → | Jul 2, 7:06 pm EDT | Jonathan ZalevskyChief R&D Officer | 5,681 | $70.00 | $397,670 | 9,756 | −36.8% | 10b5-1 |
| Jun 16, 2026 SForm 4 → | Jun 18, 7:08 pm EDT | Howard W RobinPresident & CEO, Director | 20,000 | $60.75 | $1,215,056 | 55,045 | −26.7% | 10b5-1 |
| Jun 15, 2026 SForm 4 → | Jun 17, 7:12 pm EDT | Jonathan ZalevskyChief R&D Officer | 5,538 | $60.71 | $336,212 | 15,437 | −26.4% | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 AForm 4 → | Sep 25, 8:29 pm EDT | Roy A WhitfieldDirector | 4,000 | — | — | 4,000 | — | |
| Sep 23, 2026 AForm 4 → | Sep 25, 8:26 pm EDT | R Scott GreerDirector | 4,000 | — | — | 4,000 | — | |
| Sep 23, 2026 AForm 4 → | Sep 25, 8:22 pm EDT | Robert ChessDirector | 4,000 | — | — | 4,000 | — | |
| Sep 23, 2026 AForm 4 → | Sep 25, 8:20 pm EDT | Diana BrainardDirector | 4,000 | — | — | 4,000 | — | |
| Sep 23, 2026 AForm 4 → | Sep 25, 8:18 pm EDT | Jeffrey Robert AjerDirector | 4,000 | — | — | 4,000 | — | |
| Jul 24, 2026 AForm 4 → | Jul 24, 6:35 pm EDT | Jonathan ZalevskyChief R&D Officer | 16,500 | — | — | 16,500 | — | |
| Jul 24, 2026 AForm 4 → | Jul 24, 6:34 pm EDT | Howard W RobinPresident & CEO, Director | 57,200 | — | — | 57,200 | — |